–NDR takeaways:Strong order backlog in 2H23E; Solid pipeline to drive growth into FY24/25E
China Consumer Sector: Strong recovery and sustainability during CNY
Inline 3Q23 results; strong music subscription revenue growth
–Strong sales momentum continued in 3Q
Expect strong sales in 2023 driven by the US approval of zanubrutinib in CLL
Strong cRPO growth and GenAI momentum
Expect strong growth to continue after the impressive 1H23; U/G to BUY
–Strong 3Q results on accelerating AI revenue
1Q24 beat on strong music business growth and GPM expansion
Core educational business sustained strong momentum